Vol. 10, Issue 11 (2021)

Author(s):
Rashmi Rajashekaraiah, P Ravi Kumar, N Prakash, G Srinivasa Rao, V Rama Devi, M Metta, U Sunilchandra and CR Santhosh

Abstract:
Cancer is the second leading cause of death globally, despite good advances in tumor biology research and chemotherapy. Major obstacles in cancer treatment arise from tumor heterogeneity, drug resistance, and systemic toxicities. 6-thioguanine (6-TG), a thiopurine has been used extensively in the treatment of acute leukemias since the 1940s. In this study, we investigated the cytotoxicity potential of 6-thioguanine (6-TG) on the Human cervical carcinoma cell line (HeLa). The percent cell viability was determined by conducting MTT [3-(4, 5- dimethylthiazolyl- 2)-2, 5- diphenyltetrazolium bromide] assay at 48h incubation. IC50 values of 6-TG for HeLa was 28.79μM. This study suggested that the cytotoxicity potential in terms of percent cell viability for 6-TG is dose-dependent.